Fulcrum Therapeutics (FULC) Stock Forecast & Price Target

Compare

518 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FULC Analyst Ratings

Moderate Buy

9 Buy

1 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Fulcrum

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FULC Stock 12 Month Forecast

Average Price Target

$16.80

▲(60.15% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $16.80 with a high forecast of $25.00 and a low forecast of $7.00. The average price target represents a 60.15% change from the last price of $10.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.72,11.81846153846154,12.916923076923077,14.015384615384615,15.113846153846154,16.212307692307693,17.310769230769232,18.409230769230767,19.50769230769231,20.606153846153845,21.704615384615387,22.803076923076922,23.90153846153846,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.72,11.18769230769231,11.655384615384616,12.123076923076924,12.590769230769231,13.05846153846154,13.526153846153846,13.993846153846155,14.461538461538462,14.92923076923077,15.396923076923077,15.864615384615385,16.332307692307694,{"y":16.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.72,10.433846153846154,10.147692307692308,9.861538461538462,9.575384615384616,9.28923076923077,9.003076923076923,8.716923076923077,8.430769230769231,8.144615384615385,7.858461538461539,7.572307692307692,7.286153846153846,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.7,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$16.80

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

$18

Buy

71.59%

Upside

Reiterated

02/02/26

Truist Financial Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

Tazeen Ahmad

Bank of America Securities

Sell

-33.27%

Downside

Reiterated

01/27/26

Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

01/26/26

De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data

James Condulis

Stifel Nicolaus

$20

Buy

90.66%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Fulcrum Therapeutics (NASDAQ: FULC) and Novan (NASDAQ: NOVN)

Andrew Fein

H.C. Wainwright

$18→$25

Buy

138.32%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics price target raised to $25 from $18 at H.C. WainwrightFulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright

Matthew Biegler

Oppenheimer

$15

Buy

42.99%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics (FULC) Receives a Buy from Oppenheimer

Edward Tenthoff

Piper Sandler

$16→$23

Buy

119.26%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics price target raised to $23 from $16 at Piper SandlerFulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$15

Buy

42.99%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics (FULC) Receives a Buy from Roth MKM

Luca Issi

RBC Capital

$7→$10

Hold

-4.67%

Downside

Reiterated

12/07/25

Fulcrum Therapeutics (FULC) Receives a Hold from RBC Capital

Kristen Kluska

Cantor Fitzgerald

$15

Buy

42.99%

Upside

Reiterated

12/06/25

Cantor Fitzgerald Remains a Buy on Fulcrum Therapeutics (FULC)

Joseph Schwartz

Leerink Partners

$20

Buy

90.66%

Upside

Reiterated

11/19/25

Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

$18

Buy

71.59%

Upside

Reiterated

02/02/26

Truist Financial Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

Tazeen Ahmad

Bank of America Securities

Sell

-33.27%

Downside

Reiterated

01/27/26

Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

01/26/26

De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data

James Condulis

Stifel Nicolaus

$20

Buy

90.66%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Fulcrum Therapeutics (NASDAQ: FULC) and Novan (NASDAQ: NOVN)

Andrew Fein

H.C. Wainwright

$18→$25

Buy

138.32%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics price target raised to $25 from $18 at H.C. WainwrightFulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright

Matthew Biegler

Oppenheimer

$15

Buy

42.99%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics (FULC) Receives a Buy from Oppenheimer

Edward Tenthoff

Piper Sandler

$16→$23

Buy

119.26%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics price target raised to $23 from $16 at Piper SandlerFulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$15

Buy

42.99%

Upside

Reiterated

12/08/25

Fulcrum Therapeutics (FULC) Receives a Buy from Roth MKM

Luca Issi

RBC Capital

$7→$10

Hold

-4.67%

Downside

Reiterated

12/07/25

Fulcrum Therapeutics (FULC) Receives a Hold from RBC Capital

Kristen Kluska

Cantor Fitzgerald

$15

Buy

42.99%

Upside

Reiterated

12/06/25

Cantor Fitzgerald Remains a Buy on Fulcrum Therapeutics (FULC)

Joseph Schwartz

Leerink Partners

$20

Buy

90.66%

Upside

Reiterated

11/19/25

Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fulcrum Therapeutics

3 Months

xxx

Success Rate

6/11 ratings generated profit

Average Return

+8.14%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +8.14% per trade.

1 Year

Matthew BieglerOppenheimer

Success Rate

10/18 ratings generated profit

Average Return

+37.08%

reiterated a buy rating 2 months ago

Copying Matthew Biegler's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +37.08% per trade.

2 Years

xxx

Success Rate

10/18 ratings generated profit

Average Return

+29.74%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +29.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FULC Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FULC has received 23 Buy Ratings, 25 Hold Ratings, and 3 Sell Ratings. FULC average Analyst price target in the past 3 months is 16.80.

Each month's total comprises the sum of three months' worth of ratings.

FULC Financial Forecast

FULC Earnings Forecast

Next quarter’s earnings estimate for FULC is -$0.30 with a range of -$0.33 to -$0.25. The previous quarter’s EPS was -$0.31. FULC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year FULC has Performed in-line its overall industry.

FULC Sales Forecast

Next quarter’s sales forecast for FULC is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. FULC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year FULC has Performed in-line its overall industry.

FULC Stock Forecast FAQ

What is FULC’s average 12-month price target, according to analysts?

Based on analyst ratings, Fulcrum Therapeutics’s 12-month average price target is 16.80.

What is FULC’s upside potential, based on the analysts’ average price target?

Fulcrum Therapeutics has 60.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FULC a Buy, Sell or Hold?

Fulcrum Therapeutics has a consensus rating of Moderate Buy which is based on 9 buy ratings, 1 hold ratings and 1 sell ratings.

What is Fulcrum Therapeutics’s price target?

The average price target for Fulcrum Therapeutics is 16.80. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 60.15% Increase from the current price of $10.49.

What do analysts say about Fulcrum Therapeutics?

Fulcrum Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of FULC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Fulcrum Therapeutics (FULC) Stock Forecast & Price Target

FULC Analyst Ratings

FULC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Fulcrum Therapeutics

FULC Analyst Recommendation Trends

FULC Financial Forecast

FULC Earnings Forecast

FULC Sales Forecast

FULC Stock Forecast FAQ

Detailed List of Analyst Forecasts